Gandhi Sonal, Verma Sunil
University of Toronto, Toronto, ON, Canada.
Breast Cancer Res Treat. 2007 Nov;106(1):1-9. doi: 10.1007/s10549-006-9470-y. Epub 2007 Jan 9.
Recent advances in breast cancer treatment include the advent of aromatase inhibitors (AIs) in the adjuvant setting with better efficacy and toxicity profiles than tamoxifen. However, AIs generally do not improve lipid profile as tamoxifen does, and there has been suggestion of increased cardiovascular risk with AI use. This has become an area of concern, particularly in light of the view that tamoxifen may protect against cardiovascular disease. This review of the current literature and updated trial data examines the effect both AIs and tamoxifen have on lipids and cardiovascular risk. It also highlights the importance of interpreting such data within the larger context of cardiovascular health in postmenopausal women.
乳腺癌治疗的最新进展包括芳香化酶抑制剂（AIs）在辅助治疗中的应用，其疗效和毒性特征优于他莫昔芬。然而，与他莫昔芬不同，AIs一般不会改善血脂情况，且有研究表明使用AIs会增加心血管疾病风险。这已成为一个备受关注的领域，尤其是考虑到他莫昔芬可能预防心血管疾病这一观点。这篇对当前文献和最新试验数据的综述探讨了AIs和他莫昔芬对血脂及心血管疾病风险的影响。它还强调了在绝经后女性心血管健康这一更大背景下解读此类数据的重要性。
